We are a life science innovation center that supports health tech entrepreneurs providing strategic mentorship and resources, experts and office space for growth.
THE MISSION
To accompany health tech startups to their next significant valuation milestones.
OFFERS
Neighborhood offers tailed in-residence mentoring, coaching and global access to health tech entrepreneurs.
Last events
Roundup of J.P. Morgan’s Annual Healthcare Conference
How to obtain a market approval for a health tech application or a software?
COMMUNITY
HOW TO APPLY
Tell us about your idea, technology, or innovation and how we can work together to empower you to reach your next milestone in product development.
Would like to learn more
on our programs or take a tour?
THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France
WEBSITE
https://www.op2lysis.com
OP2lysis
Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France
WEBSITE
https://www.op2lysis.com
OP2lysis
Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France
WEBSITE
https://www.op2lysis.com
OP2lysis
Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.
THERAPEUTIC AREA
Pharmacodynamic Modeling and Artificial Intelligence
LOCATION COUNTRY
Paris, France
Hillo
Hillo develops the first AI-based decision support platform for diabetic patients, based on a blood glucose levels predictive system that adapts to every patient’s physiology and habits. Our technology combines pharmacodynamic modeling and artificial intelligence, we develop tools for patients to help them anticipate and avoid hypo- or hyperglycemia, and for care teams to help them understand each patient’s specific glycemic response. We’ve demonstrated outstanding results and accuracy of our predictive technology through trials in hospitals.
THERAPEUTIC AREA
Neuropathies
LOCATION COUNTRY
Paris, France
Neurophoenix
THERAPEUTIC AREA
Neuropathies
LOCATION COUNTRY
Paris, France
Aivision